231 related articles for article (PubMed ID: 35621218)
1. Are thyrotropin-releasing hormone (TRH) and analog taltirelin viable reversal agents of opioid-induced respiratory depression?
Algera MH; Cotten JF; van Velzen M; Niesters M; Boon M; Shoham DS; Dandrea KE; van der Schrier R; Dahan A
Pharmacol Res Perspect; 2022 Jun; 10(3):e00974. PubMed ID: 35621218
[TBL] [Abstract][Full Text] [Related]
2. Intravenous and Intratracheal Thyrotropin Releasing Hormone and Its Analog Taltirelin Reverse Opioid-Induced Respiratory Depression in Isoflurane Anesthetized Rats.
Boghosian JD; Luethy A; Cotten JF
J Pharmacol Exp Ther; 2018 Jul; 366(1):105-112. PubMed ID: 29674333
[TBL] [Abstract][Full Text] [Related]
3. Respiratory effects of thyrotropin-releasing hormone and its analogue taltirelin on opioid-induced respiratory depression.
Algera MH; Cotten JF; van Velzen M; Niesters M; Boon M; Shoham DS; Dandrea KE; van der Schrier R; Dahan A
Br J Anaesth; 2022 Jul; 129(1):e4-e6. PubMed ID: 35459532
[No Abstract] [Full Text] [Related]
4. Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal.
Algera MH; Kamp J; van der Schrier R; van Velzen M; Niesters M; Aarts L; Dahan A; Olofsen E
Br J Anaesth; 2019 Jun; 122(6):e168-e179. PubMed ID: 30915997
[TBL] [Abstract][Full Text] [Related]
5. Differential activating effects of thyrotropin-releasing hormone and its analog taltirelin on motor output to the tongue musculature in vivo.
Liu WY; Liu H; Aggarwal J; Huang ZL; Horner RL
Sleep; 2020 Sep; 43(9):. PubMed ID: 32227104
[TBL] [Abstract][Full Text] [Related]
6. Reversal of hemorrhagic shock in rats using the metabolically stable thyrotropin-releasing hormone analog taltirelin hydrate.
Asai H; Watanabe Y; Yamauchi-Kohno R; Doi O
J Recept Signal Transduct Res; 2011 Dec; 31(6):416-22. PubMed ID: 22044177
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of Breathing Stimulants for Reversal of Synthetic Opioid-Induced Respiratory Depression in Conscious Rats.
Dandrea KE; Cotten JF
J Pharmacol Exp Ther; 2021 Aug; 378(2):146-156. PubMed ID: 34021024
[TBL] [Abstract][Full Text] [Related]
8. Thyrotropin-releasing hormone analog as a stable upper airway-preferring respiratory stimulant with arousal properties.
Liu WY; Ladha R; Liu H; Horner RL
J Appl Physiol (1985); 2022 Nov; 133(5):1067-1080. PubMed ID: 36135952
[TBL] [Abstract][Full Text] [Related]
9. Non-analgesic effects of opioids: opioid-induced respiratory depression.
Boom M; Niesters M; Sarton E; Aarts L; Smith TW; Dahan A
Curr Pharm Des; 2012; 18(37):5994-6004. PubMed ID: 22747535
[TBL] [Abstract][Full Text] [Related]
10. The synthetic TRH analogue taltirelin exerts modality-specific antinociceptive effects via distinct descending monoaminergic systems.
Tanabe M; Tokuda Y; Takasu K; Ono K; Honda M; Ono H
Br J Pharmacol; 2007 Feb; 150(4):403-14. PubMed ID: 17220907
[TBL] [Abstract][Full Text] [Related]
11. Stimulant effect of thyrotropin-releasing hormone and its analog, RGH 2202, on the diaphragm respiratory activity, and their antagonism with morphine: possible involvement of the N-methyl-D-aspartate receptors.
Kharkevich DA; Chizh BA; Kasparov SA
Brain Res; 1991 Jun; 551(1-2):110-5. PubMed ID: 1833029
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of opioid-induced respiratory depression.
Baldo BA; Rose MA
Arch Toxicol; 2022 Aug; 96(8):2247-2260. PubMed ID: 35471232
[TBL] [Abstract][Full Text] [Related]
13. Opioid-induced respiratory effects: new data on buprenorphine.
Dahan A
Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
[TBL] [Abstract][Full Text] [Related]
14. [Synthesis and pharmacological action of TRH analog peptide (Taltirelin)].
Yamamura M; Suzuki M; Matsumoto K
Nihon Yakurigaku Zasshi; 1997 Oct; 110 Suppl 1():33P-38P. PubMed ID: 9503402
[TBL] [Abstract][Full Text] [Related]
15. Lack of behavioral tolerance by repeated treatment with taltirelin hydrate, a thyrotropin-releasing hormone analog, in rats.
Asai H; Asahi T; Yamamura M; Yamauchi-Kohno R; Saito A
Pharmacol Biochem Behav; 2005 Dec; 82(4):646-51. PubMed ID: 16368129
[TBL] [Abstract][Full Text] [Related]
16. Advances in Reversal Strategies of Opioid-induced Respiratory Toxicity.
van der Schrier R; Dahan JDC; Boon M; Sarton E; van Velzen M; Niesters M; Dahan A
Anesthesiology; 2022 Apr; 136(4):618-632. PubMed ID: 34958670
[TBL] [Abstract][Full Text] [Related]
17. Effect of rovatirelin, a novel thyrotropin-releasing hormone analog, on the central noradrenergic system.
Ijiro T; Nakamura K; Ogata M; Inada H; Kiguchi S; Maruyama K; Nabekura J; Kobayashi M; Ishibashi H
Eur J Pharmacol; 2015 Aug; 761():413-22. PubMed ID: 26142830
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of viable mechanism agnostic respiratory stimulants for the reversal of drug-induced respiratory depression in humans.
van Lemmen M; van der Schrier R; Dahan A; van Velzen M; Sarton E; Niesters M
Expert Opin Drug Metab Toxicol; 2023; 19(10):671-679. PubMed ID: 37795596
[TBL] [Abstract][Full Text] [Related]
19. Opioid-induced respiratory depression in paediatrics: a review of case reports.
Niesters M; Overdyk F; Smith T; Aarts L; Dahan A
Br J Anaesth; 2013 Feb; 110(2):175-82. PubMed ID: 23248093
[TBL] [Abstract][Full Text] [Related]
20. Contribution of the caudal medullary raphe to opioid induced respiratory depression.
Palkovic B; Cook-Snyder D; Callison JJ; Langer TM; Nugent R; Stuth EAE; Zuperku EJ; Stucke AG
Respir Physiol Neurobiol; 2022 May; 299():103855. PubMed ID: 35124284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
